1
|
Nahand JS, Bokharaei-Salim F, Karimzadeh M, Moghoofei M, Karampoor S, Mirzaei HR, Tbibzadeh A, Jafari A, Ghaderi A, Asemi Z, Mirzaei H, Hamblin MR. MicroRNAs and exosomes: key players in HIV pathogenesis. HIV Med 2020; 21:246-278. [PMID: 31756034 PMCID: PMC7069804 DOI: 10.1111/hiv.12822] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/10/2019] [Indexed: 12/29/2022]
Abstract
OBJECTIVES HIV infection is well known to cause impairment of the human immune system, and until recently was a leading cause of death. It has been shown that T lymphocytes are the main targets of HIV. The virus inactivates T lymphocytes by interfering with a wide range of cellular and molecular targets, leading to suppression of the immune system. The objective of this review is to investigate to what extent microRNAs (miRNAs) are involved in HIV pathogenesis. METHODS The scientific literature (Pubmed and Google scholar) for the period 1988-2019 was searched. RESULTS Mounting evidence has revealed that miRNAs are involved in viral replication and immune response, whether by direct targeting of viral transcripts or through indirect modulation of virus-related host pathways. In addition, exosomes have been found to act as nanoscale carriers involved in HIV pathogenesis. These nanovehicles target their cargos (i.e. DNA, RNA, viral proteins and miRNAs) leading to alteration of the behaviour of recipient cells. CONCLUSIONS miRNAs and exosomes are important players in HIV pathogenesis. Additionally, there are potential diagnostic applications of miRNAs as biomarkers in HIV infection.
Collapse
Affiliation(s)
- Javid Sadri Nahand
- Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Farah Bokharaei-Salim
- Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Mohammad Karimzadeh
- Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Mohsen Moghoofei
- Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Sajad Karampoor
- Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Hamid Reza Mirzaei
- Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Alireza Tbibzadeh
- Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Amir Jafari
- Department of Medical Nanotechnology, Faculty of Advanced Technology in Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Amir Ghaderi
- Department of Addiction Studies, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
| | - Zatollah Asemi
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, I.R. Iran
| | - Hamed Mirzaei
- Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, I.R. Iran
| | - Michael R. Hamblin
- Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, 40 Blossom Street, Boston, MA, 02114, USA
| |
Collapse
|
2
|
Guo J, Jin D, Wu Y, Yang L, Du J, Gong K, Chen W, Dai J, Miao S, Xi S. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. EBioMedicine 2018; 35:204-221. [PMID: 30146342 PMCID: PMC6419862 DOI: 10.1016/j.ebiom.2018.08.001] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Revised: 07/23/2018] [Accepted: 08/01/2018] [Indexed: 12/11/2022] Open
Abstract
Cisplatin (DDP) resistance has become the leading cause
of mortality in non-small cell lung cancer (NSCLC). miRNA dysregulation
significantly contributes to tumor progression. In this study, we found that
miR-495 was significantly downregulated in lung cancer tissue specimens. This
study aimed to elucidate the functions, direct target genes, and molecular
mechanisms of miR-495 in lung cancer. miR-495 downregulated its substrate UBE2C
through direct interaction with UBE2C 3′- untranslated region. UBE2C is a
proto-oncogene activated in lung cancer; however, its role in chemotherapeutic
resistance is unclear. Herein, UBE2C expression levels were higher in
DDP-resistant NSCLC cells; this was associated with the proliferation, invasion,
and DDP resistance in induced cisplatin-resistant NSCLC cells. Furthermore,
epithelial–mesenchymal transitions (EMT) contributed to DDP resistance.
Moreover, UBE2C knockdown downregulated vimentin. In contrast, E-cadherin was
upregulated. Importantly, miR-495 and UBE2C were associated with cisplatin
resistance. We attempted to evaluate their effects on cell proliferation and
cisplatin resistance. We also performed EMT, cell migration, and invasion assays
in DDP-resistant NSCLC cells overexpressing miR-495 and under-expressing UBE2C.
Furthermore, in silico assays coupled with western blotting and luciferase
assays revealed that UBE2C directly binds to the 5′-UTR of the drug-resistance
genes ABCG2 and ERCC1.
Furthermore, miR-495 downregulated ABCG2 and
ERCC1 via regulation of UBE2C. Together, the present
results indicate that the miR495-UBE2C-ABCG2/ERCC1 axis reverses DDP resistance
via downregulation of anti-drug genes and reducing EMT in DDP-resistant NSCLC
cells.
Collapse
Affiliation(s)
- Jiwei Guo
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China.
| | - Dan Jin
- Department of Pain Management, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Yan Wu
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Lijuan Yang
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Jing Du
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Kaikai Gong
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Weiwei Chen
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Juanjuan Dai
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Shuang Miao
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China
| | - Sichuan Xi
- Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China
| |
Collapse
|